The Effect of Myo-inositol, Somatropin, and DHEA on Poor Ovarian Responders

Launched by BENI-SUEF UNIVERSITY · Jun 4, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of three different treatments—Myo-inositol, somatropin, and DHEA—on women who have difficulty producing eggs, known as poor ovarian responders. Poor ovarian response means that a woman has fewer than 7 small sacs in her ovaries (called antral follicles) or a low level of a hormone called anti-Mullerian hormone (less than 1.2 ng/ml). The goal is to see if these treatments can improve the chances of success for a specific fertility procedure called ICSI, which is used to help couples conceive.

To be eligible for this trial, participants must be women aged between 18 and 39 who are experiencing infertility and meet the criteria for poor ovarian response. However, certain health conditions, like polycystic ovary syndrome or diabetes, and certain pelvic issues would prevent someone from joining. This trial is not yet recruiting participants, but if you qualify, you could expect to receive one of the treatments and be monitored throughout the process to assess its effects on your fertility. This research could potentially lead to better options for women facing challenges in getting pregnant.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1-Infertile women who have one of the criteria of poor ovarian response as follows ;
• • Antral follicle count less than 7
• • Anti-Mullerian hormone level Less than 1.2 ng/ml 2- females with body mass index (BMI) from 19-25
• Exclusion Criteria:
• • 1. Any endocrine or metabolic disorder such as polycystic ovary syndrome,
• • 2. Hyperprolactinemia, diabetes and thyroid dysfunction.
• • 3. Any pelvic pathology such as hydrosalpinx, uterine anomaly.
• • 4. any male factor infertility such as Oligo-Astheno-Teratozoospermia (OAT) or Azoospermia.